dc.contributor.author | Tepekule, Burcu | |
dc.contributor.author | Abel zur Wiesch, Pia | |
dc.contributor.author | Kouyos, Roger D. | |
dc.contributor.author | Bonhoeffer, Sebastian | |
dc.date.accessioned | 2020-03-26T08:38:36Z | |
dc.date.available | 2020-03-26T08:38:36Z | |
dc.date.issued | 2019-10-30 | |
dc.description.abstract | To understand how antibiotic use affects the risk of a resistant infection, we present a computational model of the population dynamics of gut microbiota including antibiotic resistance-conferring plasmids. We then describe how this model is parameterized based on published microbiota data. Finally, we investigate how treatment history affects the prevalence of resistance among opportunistic enterobacterial pathogens. We simulate treatment histories and identify which properties of prior antibiotic exposure are most influential in determining the prevalence of resistance. We find that resistance prevalence can be predicted by 3 properties, namely the total days of drug exposure, the duration of the drug-free period after last treatment, and the center of mass of the treatment pattern. Overall this work provides a framework for capturing the role of the microbiome in the selection of antibiotic resistance and highlights the role of treatment history for the prevalence of resistance. | en_US |
dc.identifier.citation | Tepekule, Abel zur Wiesch P, Kouyos RD, Bonhoeffer S. Quantifying the impact of treatment history on plasmid-mediated resistance evolution in human gut microbiota. Proceedings of the National Academy of Sciences of the United States of America. 2019;116(46):23106-23116 | en_US |
dc.identifier.cristinID | FRIDAID 1761539 | |
dc.identifier.doi | 10.1073/pnas.1912188116 | |
dc.identifier.issn | 0027-8424 | |
dc.identifier.issn | 1091-6490 | |
dc.identifier.uri | https://hdl.handle.net/10037/17858 | |
dc.language.iso | eng | en_US |
dc.publisher | National Academy of Sciences | en_US |
dc.relation.journal | Proceedings of the National Academy of Sciences of the United States of America | |
dc.relation.projectID | Norges forskningsråd: 187615 | en_US |
dc.relation.projectID | info:eu-repo/grantAgreement/RCN/EMBLNODE/187615/Norway/Norsk senter for molekylærmedisin (NCMM) - Centre for Molecular Medicine Norway - Nordic EMBL Partnership// | en_US |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2019 The Author(s) | en_US |
dc.subject | VDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Pharmacology: 728 | en_US |
dc.subject | VDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Farmakologi: 728 | en_US |
dc.title | Quantifying the impact of treatment history on plasmid-mediated resistance evolution in human gut microbiota | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |